TERN is no longer listed. Its last trade on record was May 15, 2026. The price and figures on this page are from its last trading day and final filings, and are no longer updated.
TERN trades 2.9% above Wall Street's consensus target of $51.40.
Last 12 months price action with 12-month analyst target path
The base valuation assumes TERN achieves its forward estimates and maintains a stable P/E multiple of historical averagesx. This scenario reflects the blended consensus of 16 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of November 8, 2026, Terns Pharmaceuticals, Inc. (TERN) has a Wall Street consensus price target of $51.40, based on estimates from 16 covering analysts.
Analyst price targets range from a low of $14.00 to a high of $70.00, representing a 109% spread in expectations. The median target of $56.00 differs from the mean, suggesting potential outlier estimates. The wide target spread reflects significant disagreement on fair value.
The current analyst consensus rating is Buy, with 10 analysts rating the stock as a Buy or Strong Buy,6 rating it Hold, and 0 rating it Sell or Strong Sell. The positive sentiment balance indicates moderate optimism about the stock prospects.
From a valuation perspective, TERN trades at a. Analysts expect EPS to grow -12.0% over the next year.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
 MDGLMadrigal Pharmaceuticals, Inc. | $9.2B | $399.63 | $684.80 | +71.4% | Buy | — | 25 |
 HIMSHims & Hers Health, Inc. | $5.8B | $26.00 | $32.17 | +23.7% | Hold | — | 20 |
 ELVNEnliven Therapeutics, Inc. | $3.5B | $49.43 | $76.29 | +54.3% | Buy | — | 9 |
 GPCRStructure Therapeutics Inc. | $1.2B | $20.35 | $90.50 | +344.7% | Buy | — | 14 |
 VKTXViking Therapeutics, Inc. | $3.1B | $26.84 | $82.00 | +205.5% | Buy | — | 24 |
 ARWRArrowhead Pharmaceuticals, Inc. | $8.2B | $58.16 | $101.56 | +74.6% | Buy | — | 22 |
 ALDXAldeyra The | $38M | $0.63 | $9.67 | +1426.0% | Buy | — | 19 |
 HALOHalozyme Therapeutics, Inc. | $12.3B | $103.63 | $110.00 | +6.1% | Buy | 12.0x | 27 |
 INVAInnoviva, Inc. | $1.4B | $19.10 | $38.00 | +99.0% | Buy | 7.9x | 11 |
 CGEMCullinan Therapeutics, Inc. | $695M | $11.31 | $35.00 | +209.5% | Buy | — | 8 |
Quick answers to the most common questions about buying TERN stock.
Wall Street's consensus price target for TERN is $51.4, -2.9% from its current price of $N/A. The below-market target from 16 analysts suggests limited near-term appreciation.
TERN has a consensus rating of "Buy" based on 16 Wall Street analysts. The rating breakdown is predominantly bullish, with 10 Buy/Strong Buy ratings. The consensus 12-month price target of $51.4 implies -2.9% downside from current levels.
TERN's current price is $N/A with a consensus target of $51.4 (-2.9% implied move). Analyst estimates suggest the stock is fairly valued at current levels.
The most bullish Wall Street analyst has a price target of $70 for TERN, while the most conservative target is $14. The consensus of $51.4 represents the median expectation. These targets typically reflect 12-month expectations.
TERN is well covered by analysts, with 16 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 10 have Buy ratings, 6 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month TERN stock forecast based on 16 Wall Street analysts shows a consensus price target of $51.4, with estimates ranging from $14 (bear case) to $70 (bull case). The median consensus rating is "Buy".
Analysts are cautious on TERN, with 0 Sell ratings and a price target of $51.4 (-2.9% from current price). The "Buy" consensus suggests careful evaluation before buying. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
TERN analyst price targets range from $14 to $70, a 109% wide spread indicating significant analyst disagreement. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $51.4 consensus represents the middle ground.
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.